Working title: Health-related quality of life of female sex workers living with HIV in South Africa

Authors: Linwei Wang[1], David W. Dowdy[2], Carly A. Comins[2], Katherine Young[3], Mfezi Mcingana[3], Ntambue Muluba[3], Hlengiwe Mhlophe[3], Claire Chen[2], Harry Hausler[3], Sheree R. Schwartz[2], Stefan Baral[2], Sharmistha Mishra[1,4,5,6], on behalf of the Siyaphambili Study team

Affiliations: [1]MAP-Centre for Urban Health Solutions, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada; [2]Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA; [3] TB HIV Care, South Africa; [4]Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada; [5]Department of Medicine, Division of Infectious Disease, University of Toronto, Toronto, ON, Canada; [6]Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada.

Corresponding Author:
Sharmistha Mishra, MD, MSc, PhD
MAP-Centre for Urban Health Solutions
St. Michael's Hospital, Unity Health Toronto
University of Toronto
209 Victoria St, Toronto, ON M5B 1T8
E: sharmistha.mishra@utoronto.ca
T: 416-864-5746

Word Count: 3502/3500
Tables: 3
Figures: 2
Last updated: June 1, 2021

ABSTRACT [287/300]

Background: Health-related quality of life (HRQoL) is an important HIV outcome beyond viral suppression. However, there are limited data characterizing HRQoL of key populations including female sex workers (FSW) living with HIV.

Methods: We used baseline data (2018-2020) of FSW who were diagnosed with HIV and enrolled into a randomized trial in Durban, South Africa. HRQoL information was collected by a generic preference-based tool with five domains (EQ-5D), and summarized into a single score (range 0-1) which represents health utility. We employed multivariable beta regression models to identify determinants of HRQoL and to estimate subgroup-specific HRQoL score.

Findings: Of 1363 individuals (mean age: 32.4 years; mean HRQoL score: 0.857) in our analysis, 62.6% used drugs, 61.3% experienced physical or sexual violence, and 64.6% self-reported taking antiretroviral treatment (ART). The following were associated with a reduction in the average marginal HRQoL score: older age (per decade: 0.018 [95% confidence interval (CI): 0.008, 0.027]), drug use (0.022 [0.007, 0.036]), experience of violence (0.024 [0.010, 0.038]), and moderate (vs. no) level of internalized stigma (0.023 [0.004, 0.041]). Current ART use was associated with a 0.015-point (-0.001, 0.031) increase in the HRQoL score. The estimated mean (95%CI) HRQoL scores ranged from 0.838 (0.816, 0.860) for FSW who used drugs, experienced violence, and were not on ART; to 0.899 (0.883, 0.916) for FSW who did not use drugs nor experience violence and were on ART.

Interpretation: These results demonstrate the association of ART with higher HRQoL among FSW and the need to further address structural risks including drug use, violence, and stigma. Population-specific estimates of HRQoL score can be further used to calculate quality-adjusted life years in economic evaluations of individual and structural interventions addressing the needs of FSW living with HIV.

Funding: National Institutes of Health (R01NR016650)

RESEARCH IN CONTEXT

Evidence before this study

We searched PubMed on April 9, 2021 for studies published in English that examined the health-related quality of life of female sex workers (FSW) living with HIV. We used the search terms ("quality of life") AND ("sex workers") AND (“HIV”). Our search resulted in a total of 14 studies. We excluded 6 studies as their study sample did not include female sex workers; and another 2 studies as they were mathematical modeling or cost-effectiveness analyses which did not include original data. Of the remaining 6 studies, 5 were among FSW in general, regardless of their HIV status; we only identified one study that specifically examined the quality of life in FSW living with HIV: among 98 HIV-positive women who were former commercial sex workers in Nepal, the authors examined the degree to which indicators of physical, mental, and social domains explained variation in overall perceived life satisfaction. Of the 5 studies among FSW in general, 3 were qualitative studies, one was a quantitative individual-level study, and one was a systematic review and meta-analysis. The meta-analysis of eight studies (China, India, Korea, Philippines, Puerto Rico, Armenia, and the United States) published before July 2013 found that increased psychological health conditions were associated with increased HIV risk behavior. By searching citations of the above systematic review, we identified another more recent meta-analysis which examined the prevalence and risk factors of mental health conditions among FSW in low and middle income countries. This meta-analysis included 56 unique studies published up to April 2020, demonstrating prevalent mental health conditions among FSW in low- and middle-income settings, with increased burden of mental health conditions associated with experiences of violence, harmful alcohol and drug use, inconsistent condom use, and HIV incidence. In summary, although mental health conditions of FSW have been broadly explored in the literature, there remains a dearth of research which evaluated health-related quality of life of FSW living with HIV.

Added value of this study

We directly evaluated the HRQoL of FSW living with HIV in South Africa. We used data on a sample of FSW who were diagnosed with HIV and enrolled into a randomized trial via a local sex worker program in Durban. Our comprehensive baseline questionnaire allowed us to examine a range of factors (sociodemographic characteristics, clinical features and treatment of HIV, drug use and other social and structural factors) and their relationship with HRQoL among FSW living with HIV. The average HRQoL score was 0.857 for FSW living with HIV. We identified older age, lack of ART use, drug use, and experience of violence as being associated with a lower HRQoL score among FSW living with HIV. We did not find an independent association between CD4 count or viral load with HRQoL score after adjusting for current ART use and other covariates. In addition, we derived overall and subgroup-specific estimates of HRQoL scores, representing health utilities, which can be used to calculate quality-adjusted life-years in cost utility analysis for economic evaluations of interventions targeting FSW living with HIV in South Africa.

Implications of all the available evidence

The findings here reinforce the importance of comprehensive programs to optimize treatment outcomes among sex workers living with HIV. While ART is central given its association with improved quality of life for people living with HIV, a human-centered approach focused on addressing social and structural vulnerabilities including addiction services, violence, and stigma, represent critical components of optimizing quality of life among female sex workers living with HIV in South Africa.

INTRODUCTION

Globally, there has been remarkable progress towards the UNAIDS 90-90-90 HIV testing and treatment targets. By the end of 2019, 81% of people living with HIV knew their status, of whom 83% were on antiretroviral treatment (ART), and 88% of those on ART were virally suppressed[1]. Although much work remains to improve the cascade of HIV care, there is growing recognition of the importance of patient-centered chronic care to improve patient-reported outcomes such as health-related quality of life (HRQoL) for people living with HIV[2,3]. Some have proposed that good HRQoL should be explicitly included as the 'fourth 90' target as part of the HIV care cascade[3].

HRQoL is a multidimensional concept that is defined as a person's subjective perception of the impact of ill health on daily life and includes physical, psychological and social functioning[4]. Most existing studies on HRQoL among people living with HIV have identified CD4 count, gender, age, and ART use as common determinants for HRQoL[5-8]. The majority of these studies have been conducted in wider populations of people living with HIV in high income settings[7], though some have been performed in low and middle income settings including sub-Saharan Africa[6,7]. There is a dearth of research regarding HRQoL in key populations living with HIV, including female sex workers (FSW).

In South Africa, FSW have a very high burden of HIV[9]. Approximately 90,000 FSW in South Africa are estimated to be living with HIV, representing nearly 60% of all women engaged in sex work[9]. FSW living with HIV face a wide range of challenges, including underlying HIV progression, comorbidities, drug use, stigma, and other social and structural vulnerabilities[2,7,8] resulting in suboptimal treatment uptake and viral suppression[10-12]. Data, although limited, suggest that less than 40% of FSW living with HIV are virally suppressed[10]. However, it is unclear how these challenges have shaped FSW's self-perception of their well-being. A meta-analysis across 31 studies in low and middle income settings found highly prevalent mental health conditions among FSW, including depression, anxiety, post-traumatic stress disorder, and suicidal thoughts and attempts[13]. However, these studies examined FSW in general, instead of those living with HIV, and with a focus on mental health rather than overall HRQoL[13].

HRQoL as a multidimensional concept can also be summarized into a single metric of health utility, which is important for economic evaluations of HIV interventions[5,6,14]. For example, preference-based measures of HRQoL such as the EQ-5D (captures HRQoL information in five domains) are often summarized into a single score representing health utility, and used to calculate quality-adjusted life years (QALYs) to be applied in cost-utility analyses[14,15]. A review of the economic evaluation literature on HIV interventions in sub-Saharan Africa reveals that the weights assigned to QALYs often have an insufficient evidence basis due to lack of data on setting- and population-specific health utility measures[6,16].

To address these knowledge gaps, we aimed to examine HRQoL across five EQ-5D domains, estimate HRQoL scores which represent health utilities, and identify characteristics associated with HRQoL scores among FSW living with HIV in Durban, South Africa.

METHODS

Study design and subjects

The current analysis uses baseline data from an adaptive randomized intervention trial (Siyaphambili study) involving FSW in Durban, South Africa[10]. Cisgender women who were 18 years and older, selling sex as their main source of income, residing in Durban, and diagnosed with HIV at least 6 months prior to study enrollment were eligible. Study recruitment was conducted by TB HIV Care, a South African nongovernmental organization that has been providing HIV prevention and care for FSW in Durban since 2012. FSW were recruited by peer case managers in the community via mobile van outreach, and from service recipients accessing TB HIV Care services at a drop-in center. Full details of the study have been described elsewhere[10].

Following informed consent and enrollment, participants provided whole blood samples which were used to assess baseline CD4 count and viral load. Individuals completed an interviewer-administered questionnaire that elicited information including socio-demographic characteristics, personal and sexual history, HIV care and other health service utilization, drug use, and HRQoL. The study was approved by the University of the Western Cape Biomedical Research Ethics Committee in South Africa; the Johns Hopkins School of Public Health Institutional Review Board in the United States, and the eThekwini Municipality and KwaZulu-Natal Provincial Departments of Health.

All FSW recruited between June 2018 and March 2020 who completed their baseline questionnaire were included in the analysis. Individuals were excluded if their responses to the primary outcome (described below) were missing.

Measures

HRQoL information was collected using the generic preference-based measure - EuroQoL five dimension, three level questionnaire (EQ-5D-3L)[15]. The EQ-5D-3L measures HRQoL in five domains (mobility, self-care, ability to do usual activities, pain/discomfort, and anxiety/depression), and each domain is measured with three levels (1=no problems, 2=some problems/moderate problems, and 3=extreme problems). The answers can be assembled into a 5-digit health state reflecting the score on each dimension, resulting in a total of 243 plausible health states (3^5). For example, 11123 refers to a health state with no problems in mobility, self-care and usual activity; moderate problems with pain/discomfort; and extreme problems with anxiety/depression. The EQ-5D also contains a separate question which asks participants to directly rate their health state from the best (score of 100) to the worst (score of 0) (referred to as EQ visual analogue scale (EQ-VAS)). The EQ-5D has been used to measure HRQoL of the wider population and people living with HIV across high, middle, and low income settings including South Africa[6,7,17,18]. The EQ-5D is also a guideline-recommended instrument to derive health utility measures[14,19].

Our primary outcome was a summary HRQoL score, representing health utility. The HRQoL score was calculated using the 5-digit health states combined with valuations of the health states from the wider population (value set). A wider population value set is used to reflect the preferences of local taxpayers and potential receivers of healthcare in general[15]. We used the value set obtained from the population in Zimbabwe because it is the only sub-Saharan African country for which these values are available[17]. The calculated HRQoL score ranges between 0 and 1, where 0 represents a state equivalent to death and 1 represents perfect health. We chose HRQoL score as our primary measure because it represents health utility for use in cost-utility analyses.

Our secondary outcomes included the EQ-VAS, each of the EQ-5D-3L domains, and a binary variable indicating no reported problem on all five EQ-5D-3L domains (perfect health state).

We defined an a priori set of covariates to examine in the models based on evidence from the literature regarding their associations with HRQoL[6,8,20]. These covariates included sociodemographic characteristics, clinical features and treatment of HIV, drug use and other social and structural factors. Specifically, we considered age (in years), race (black/other), education (completed secondary school or higher: yes/no), ART experience (naïve/current on /off), CD4 count (≥500/350-499/200-349/<200 cells/mm^3), viral load (<50/50-1000/>1000 copies/ml), drug use in the past 30 days (yes/no), lifetime injection drug use (yes/no), experience of homelessness in the past 6 months (yes/no), lifetime experience of physical or sexual violence (yes/no), experience with stigma related to HIV or sex work (no/slight/moderate/extreme), and internalized stigma related to sex work (no/slight/moderate/extreme). Details on stigma measures are shown in **Appendix A1**. All covariates were measured at the baseline assessment, and other than CD4 count and viral load, all covariates were based on self-report.

Statistical analysis

The analysis proceeded in the following steps. First, we examined the descriptive characteristics of the study sample at baseline; assessed the distribution of our primary and secondary measures of HRQoL; and compared the differences in the HRQoL score, and of the EQ-VAS, by covariate of interest. Wilcoxon rank sum tests and Kruskal-Wallis tests were used to compare the median values in outcomes across binary variables and other categorical variables, respectively.

Second, we employed multivariable beta regression models with a complementary log-log link and fixed dispersion to investigate associations between covariates of interest and the HRQoL score[21]. Beta regression models provide a flexible approach to modeling health utility values which are truncated (ranging between 0 and 1) and skewed[21]. We provide details on model specification and selection in **Appendix A2**. We present the results as average marginal effects, which reflect the magnitude of association between a one-unit change in the covariate and the mean HRQoL score[22] – as well as the corresponding 95% confidence intervals (CIs). Using the fitted multivariable beta regression model, we estimated the mean and 95% CIs of HRQoL

score for subgroups of FSW defined by identified determinants of HRQoL score, setting the rest of covariates at the sample average values.

Third, we performed a set of multivariable regression analyses to examine the relationship between the covariates of interest and our secondary outcomes. Multivariable linear regression was used to model the EQ-VAS, and we scaled the EQ-VAS to a range of 0-1 so that the estimated magnitude of the association between covariates and EQ-VAS could be compared against that of the association with HRQoL score. Multivariable logistic regression was used to model each of the EQ-5D-3L domains, and the perfect health state, separately. We grouped each EQ-5D-3L domain into two levels (reporting some (either moderate or extreme) vs. no problems).

Lastly, to examine the sensitivity of our results to the value set used to calculate HRQoL scores, we computed a new HRQoL score using the value set obtain from the wider population in UK[18]. We repeated the multivariable beta regression analysis to examine the relationship between covariates of interest and the new HRQoL score.

All statistical analyses were executed in R version 3.6.2. R package ‘betareg’ was used for beta regression analysis[21] and R package ‘margins’ was used to estimate average marginal effects[22].

RESULTS

Of 1363 individuals included in our analysis, the majority (97.4%) self-identified as black, and the median age was 31.0 years (interquartile range: 26.6, 36.7). We excluded 28 (2.0%) individuals because they were missing the primary outcome. Overall, 853 individuals (62.6%) reported using drugs in the past 30 days, 397 (29.1%) experienced homelessness in the past six months, 835 (61.3%) ever experienced physical or sexual violence, and 1199 (88.0%) reported either experience with stigma (n=957, 70.2%) or internalized stigma (n=819, 60.1%). All individuals were diagnosed with HIV prior to study entry, of whom 178 (13.1%) self-reported being ART naïve while 880 (64.6%) reported being on ART, and 303 (22.2%) reported prior, but non-current ART use at time of enrollment. According to blood tests conducted at study entry, 510 (37.4%) individuals were virally suppressed (<50 copies/ml). **Table 1** provides details on sample characteristics.

Regarding the five domains of EQ-5D, the majority of individuals reported no problems in mobility (95.7%), self-care (99.0%), and usual activity (96.9%); while 32.9% and 40.7% reported at least some problems in pain/discomfort, and in anxiety/depression, respectively (**Figure 1A**). Of the 243 plausible health states summarized across the five EQ-5D domains (3^5), we observed 47; the 12 most frequent health states represented more than 95% of all observations (**Figure 1B**). Individuals with a perfect health state (reporting no problems in all five domains) accounted for more than half (52.5%) of the sample (**Figure 1B**). The HRQoL score was heavily left-skewed, ranging from 0.233 to 1, with a median of 1 [interquartile range: 0.787,1] and mean of 0.857 (standard deviation: 0.187) (**Figure 1C**). The EQ-VAS ranged from 0 to 100, with a median of 52.0 [50.0, 70.0] and mean of 57.7 (21.9) (**Figure 1D**).

Table 2 presents the summary statistics of HRQoL score and EQ-VAS by sample characteristic. The median HRQoL score was higher in younger individuals (1.00 vs. 0.854, comparing ages 18-34 vs. 35-64, p=0.006); individuals who identified as black (1.00 vs. 0.854, p=0.008) and reported current ART use (1.00 vs. 0.854, p=0.001), compared to their counterparts. In contrast, the median HRQoL score was lower in individuals who used drugs (0.854 vs. 1.00, p<0.001), and who experienced homelessness (0.854 vs. 1.00, p=0.014) or violence (0.854 vs. 1.00, p<0.001). We did not observe a difference in HRQoL score by CD4 count nor by viral load. However, individuals with higher CD4 counts and lower viral load had higher EQ-VAS (p<0.001, **Table 2**); and those with experience of or internalized stigma had lower EQ-VAS (p<0.001, **Table 2**).

In the multivariable regression analysis, we excluded another 87 (6.4%) individuals because they had missing covariate information. Individuals excluded from analysis were younger, less likely to be on ART, and more likely to experience homelessness compared to those who were included (**Appendix Table A3.1**). We found that age (per ten-year increase), drug use, and violence experience were associated with 0.018 (95% confidence interval (CI): 0.008, 0.027)), 0.022 (0.007, 0.036), and 0.024 (0.010, 0.038) lower average marginal HRQoL score, respectively (**Table 3**). Current ART use was associated with 0.015 (-0.001, 0.031) higher average marginal HRQoL score (**Table 3**). We did not find a difference in HRQoL score

between individuals who were ART naïve and who had previously been but were not currently on ART (results not shown; we thus combined these two groups in the regression models). Individuals with moderate internalized stigma had 0.023 (0.004, 0.041) lower average marginal HRQoL score compared to those without internalized stigma; however, we did not observe a difference between those with extreme versus no internalized stigma (**Table 3**). We did not find independent associations between education, CD4 count, viral load, homelessness, or stigma experience with HRQoL score (**Table 3**).

Based on the fitted multivariable regression model, the estimated mean (95% CI) HRQoL scores were 0.870 (0.854, 0.886) for FSW living with HIV overall, 0.877 (0.862, 0.893) and 0.862 (0.843, 0.882) for those with and without current ART use, respectively. **Figure 2** shows estimates of HRQoL score for other subgroups of FSW. For example, the model estimated mean HRQoL scores of 0.838 (0.816, 0.860) for FSW who used drugs, experienced violence, and were not on ART, versus 0.899 (0.883, 0.916) for FSW who did not use drugs nor experience violence and were on ART.

Multivariable analyses of secondary HRQoL outcomes identified some similarities and some differences in terms of variables associated HRQoL (**Table 3**; **Appendix Figure A3.1**). For example, age and drug use were not independently associated with EQ-VAS (**Table 3**). Homelessness was associated with lower EQ-VAS (-0.027 (-0.053, -0.001)) (**Table 3**). We observed a dose-response relationship between both stigma variables (experience with stigma or internalized stigma) and EQ-VAS, where increasing stigma was associated with lower EQ-VAS (**Table 3**). When we analyzed the five domains of EQ-5D separately, we found homelessness was associated with increased odds of reporting any problem in mobility (1.72 (0.95, 3.09)), and in pain/discomfort (1.46 (1.11, 1.90)) ((**Appendix Figure A3.1**).

Our sensitivity analysis using a UK-based value set in our calculation of the HRQoL score revealed similar results (**Appendix Table A3.2**).

DISCUSSION

There has been limited study of HRQoL among FSW living with HIV across Sub-Saharan Africa including the estimation of health utility. Among 1363 FSW who were diagnosed with HIV and enrolled into an adaptive randomized trial via HIV prevention and treatment program for sex workers in Durban, we found older age, lack of ART use, drug use, and experience of violence were associated with lower HRQoL score at the time of enrollment. In addition, we present the overall, and subgroup-specific estimates of HRQoL scores, which can be used to calculate QALYs in cost-utility analysis of interventions focused on FSW living with HIV in South Africa.

The observed average HRQoL score for FSW living with HIV was 0.857 (model estimated mean of 0.870 (95% CI: 0.854, 0.886)), which is somewhat lower than an estimate from the wider population living with HIV in South Africa between 2013-2015 (0.89[20]). Our findings are consistent with previous studies which found higher burden of mental health conditions among FSW in low and middle income settings compared to the wider population, though none of these studies directly estimated HRQoL as a measure of health utility[13]. The associations between lower HRQoL and drug use, as well as experience of violence, were also consistent with this recent meta-analysis[13]. Given the high prevalence of drug use (62.6%) and experience of violence (61.3%) among FSW living with HIV in our study, these findings, taken together, highlight the need for interventions to prevent and mitigate the effects of violence and drug use to help improve the well-being among sex workers. For example, assuming an average remaining life expectancy of 30 years for each FSW living with HIV[23], and an estimated 90,000 FSW living with HIV in South Africa[9], using the prevalence of drug use and experience of violence observed in our study, our results can be interpreted as a reduction in 37,184 and 39,722 QALYs related to drug use and experience of violence, respectively in South Africa.

We also observed a high prevalence of homelessness (29%) and experience of stigma or internalized stigma (88%) among FSW living with HIV in the study. Although we did not observe an independent association between experience of homelessness or stigma with HRQoL score, homelessness was associated with increased odds of reporting problems in mobility, pain/discomfort, as well as lower EQ-VAS. Similarly, we found a strong negative dose-response relationship between levels of stigma and the EQ-VAS. These findings suggest a strong negative subjective experience of stigma, even if this experience is not reflected in self-reported problems on the EQ-5D domains. Although generic preference-based measures of HRQoL such as EQ-5D allow for calculation of HRQoL scores which enables comparison across groups with different diseases, these measures may be insensitive to specific issues faced by specific populations[24]. Future studies using disease-specific HRQoL measures such as the WHOQOL-HIV BREF [25] and exploring various underlying types of stigma[26] may provide additional insights into the relationship between stigma and HRQoL among FSW living with HIV. Our findings of high prevalence of stigma and its association with poorer self-perceived overall HRQoL further highlight the need to evaluate interventions to combat intersectional stigma (e.g., the convergence of multiple stigmatized attributes) for key populations[27].

Despite heterogeneity in HRQoL across subgroups of FSW living with HIV, we found that current ART use was independently associated with higher HRQoL. These results are consistent with previous studies among the wider population[6,14,20], including studies with longitudinal design which found improvement in HRQoL following ART initiation[28]. For example, among a random sample of the wider adult population in South Africa, Thomas et al., showed that there was no difference in HRQoL among individuals on ART compared to HIV-negative individuals[20]. Collectively, these findings demonstrate the association between ART and higher HRQoL among people living with HIV, and the importance of improving ART retention.

We did not observe an independent association between CD4 count or viral load with HRQoL in our study. Although HRQoL scores (utility measures) for people living with HIV are often stratified by CD4 count (with lower CD4 counts correlated with lower weights), these estimates were obtained before ART became widely available[5]. Indeed, in the United States, more recent utility estimates have been found to be more similar across CD4 count strata and to have a narrower range than pre–ART measures[5]. Studies have shown that virally suppressed individuals still experience high levels of symptom-related distress, such as fatigue and energy loss, insomnia, sadness and depression, sexual dysfunction and changes in body appearance[29], which likely reduce their HRQoL. These results support that viral suppression is an essential but not sole end point of HIV care, and there is a need to improve HIV outcomes beyond viral suppression[2,3].

Our study has several limitations. Our sample did not include FSW living with HIV who were either undiagnosed or diagnosed recently. However, a previous study in South Africa has shown similar HRQoL score between those undiagnosed and those on ART[20]. As such, one might be able to approximate the HRQoL score for FSW living with undiagnosed HIV using our estimates of FSW on ART. Our results could be subject to selection bias to the extent that women reached by the sex worker programs and who consented to enroll into the study were different from their counterparts. Nevertheless, it is essential to study HRQoL in marginalized populations such as FSW in high-burden countries. We relied on individuals' self-report of ART use which might be affected by recall bias. In addition, we used the EQ-5D health state valuations from Zimbabwe, as valuations for South Africa were not available. However, our sensitivity analyses using UK valuations produced similar results. Our analyses were based on cross-sectional data and thus cannot be used to infer causality. Caution should be exercised when applying our estimates to FSW populations in different settings.

In summary, we evaluated the overall and characteristics associated with HRQoL for FSW living with HIV in South Africa and presented both overall and subgroup-specific estimates of HRQoL score, representing health utility. The findings here reinforce the importance of comprehensive programs to optimize treatment outcomes among sex workers living with HIV. While ART is central given its association with improved HRQoL for people living with HIV, a human-centered approach focused on addressing social and structural vulnerabilities including addiction services, violence, and stigma, represent critical components of optimizing HRQoL among FSW living with HIV in South Africa.

Role of the Funding Source

The funders of the study had no direct role in the conduct of the analysis, or in the study design, data collection, interpretation, or writing and submission of the report. The corresponding author had full access to the data and final responsibility for the decision to submit for publication.

Declaration of Interests

There are no conflicts of interest to disclose.

Acknowledgments

This study was funded by the National Institutes of Health (R01NR016650).

Author contribution

All listed authors contributed significantly to the work. LW and SM conceptualized and designed the study. CAC, KY, MM, NM, and HM contributed to the data collection. LW and CAC cleaned the data. CC provided critical inputs into data cleaning. LW conducted the data analyses, interpreted the results, and drafted the manuscript. DWD and SM provided critical inputs into the analyses. DWD, CAC, KY, MM, NM, HM, CC, HH, SRS, SB, and SS contributed to the interpretation of results and provided critical manuscript revision. KY, MM, NM, HM, and HH provided important inputs from a local programming perspectives.

REFERENCES [29/30]

1. UNAIDS. Global AIDS Update 2020. Seizing the moment: Tackling entrenched inequalities to end epidemics Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2020.
2. The Lancet H. Living well with HIV. *Lancet HIV* 2019; **6**(12): e807.
3. Lazarus JV, Safreed-Harmon K, Barton SE, et al. Beyond viral suppression of HIV - the new quality of life frontier. *BMC Med* 2016; **14**(1): 94.
4. Ferrans CE. Definitions and conceptual models of quality of life. . In: Lipscomb J GC, Snyder C, , ed. Outcomes assessment in cancer. Cambridge, England: Cambridge University; 2005: 14-30.
5. Whitham HK, Hutchinson AB, Shrestha RK, et al. Health Utility Estimates and Their Application to HIV Prevention in the United States: Implications for Cost-Effectiveness Modeling and Future Research Needs. *MDM Policy Pract* 2020; **5**(2): 2381468320936219.
6. Robberstad B, Olsen JA. The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study. *Cost Eff Resour Alloc* 2010; **8**: 5.
7. Cooper V CJ, Harding R, Whetham J,. Measuring quality of life among people living with HIV: a systematic review of reviews. *Health and quality of life outcomes* 2017; **15**(1): 1-20.
8. Drewes J, Gusy B, Ruden U. More than 20 years of research into the quality of life of people with HIV and AIDS--a descriptive review of study characteristics and methodological approaches of published empirical studies. *J Int Assoc Provid AIDS Care* 2013; **12**(1): 18-22.
9. Baral S, Beyrer C, Muessig K, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. *Lancet Infect Dis* 2012; **12**(7): 538-49.
10. Comins CA, Schwartz SR, Phetlhu DR, et al. Siyaphambili protocol: An evaluation of randomized, nurse-led adaptive HIV treatment interventions for cisgender female sex workers living with HIV in Durban, South Africa. *Res Nurs Health* 2019; **42**(2): 107-18.
11. Comins CA, Schwartz SR, Young K, et al. Contextualising the lived experience of sex workers living with HIV in South Africa: a call for a human-centred response to sexual and reproductive health and rights. *Sex Reprod Health Matters* 2019; **27**(1): 1686200.
12. Schwartz S, Lambert A, Phaswana-Mafuya N, et al. Engagement in the HIV care cascade and barriers to antiretroviral therapy uptake among female sex workers in Port Elizabeth, South Africa: findings from a respondent-driven sampling study. *Sex Transm Infect* 2017; **93**(4): 290-6.
13. Beattie TS, Smilenova B, Krishnaratne S, Mazzuca A. Mental health problems among female sex workers in low- and middle-income countries: A systematic review and meta-analysis. *PLoS Med* 2020; **17**(9): e1003297.
14. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. *Br Med Bull* 2010; **96**: 5-21.
15. EuroQol Research Foundation. EQ-5D-3L User Guide. Basic information on how to use the EQ-5D-3L instrument. Version 6.0, 2018.

16. Rinaldi G, Kiadaliri AA, Haghparast-Bidgoli H. Cost effectiveness of HIV and sexual reproductive health interventions targeting sex workers: a systematic review. *Cost Eff Resour Alloc* 2018; **16**: 63.
17. Jelsma J, Hansen K, De Weerdt W, De Cock P, Kind P. How do Zimbabweans value health states? *Popul Health Metr* 2003; **1**(1): 11.
18. Dolan P. Modeling valuations for EuroQol health states. *Med Care* 1997; **35**(11): 1095-108.
19. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. London, 2013.
20. Thomas R, Burger R, Harper A, et al. Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. *Lancet Glob Health* 2017; **5**(11): e1133-e41.
21. Cribari-Neto FaZ, A., . Beta regression in R, 2009.
22. Thomas J. Leeper. Interpreting Regression Results using Average Marginal Effects with R's margins 2021.
23. World Bank. Data country profile: South Africa. https://databank.worldbank.org/views/reports/reportwidget.aspx?Report_Name=CountryProfile&Id=b450fd57&tbar=y&dd=y&inf=n&zm=n&country=ZAF (accessed May 31 2021).
24. Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. *Pharmacoeconomics* 2006; **24**(8): 751-65.
25. World Health Organization. WHOQoL-HIV Bref. World Health Organization. In: dependence Mheardomhas, editor. Geneva; 2002.
26. Grosso AL, Ketende SC, Stahlman S, et al. Development and reliability of metrics to characterize types and sources of stigma among men who have sex with men and female sex workers in Togo and Burkina Faso. *BMC Infect Dis* 2019; **19**(1): 208.
27. Andersson GZ, Reinius M, Eriksson LE, et al. Stigma reduction interventions in people living with HIV to improve health-related quality of life. *Lancet HIV* 2020; **7**(2): e129-e40.
28. Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. *HIV AIDS (Auckl)* 2012; **4**: 117-24.
29. Erdbeer G, Sabranski M, Sonntag I, et al. Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy. *J Int AIDS Soc* 2014; **17**(4 Suppl 3): 19673.

Table 1. Characteristics of female sex workers living with HIV in Durban, South Africa, 2018-2020.

Characteristics	Total (N=1363)
Age in years	
18-24	228 (16.7%)
25-34	707 (51.9%)
35-44	314 (23.0%)
45-65	114 (8.4%)
Self-identified as Black	1327 (97.4%)
Completed secondary school or higher	263 (19.3%)
ART experience*	
ART naive	178 (13.1%)
Currently off ART	303 (22.2%)
Currently on ART	880 (64.6%)
CD4 count, cells/mm^3*	
≥500	658 (48.3%)
350-499	257 (18.9%)
200-349	207 (15.2%)
<200	162 (11.9%)
Viral load, copies/ml*	
<50	510 (37.4%)
50-1000	206 (15.1%)
>1000	642 (47.1%)
Drug use, past 30 days	853 (62.6%)
Injection drug use, ever*	54 (4.0%)
Homelessness, past 6 months*	397 (29.1%)
Experience of physical or sexual violence, ever*	835 (61.3%)
Experience with stigma, ever**	
No	406 (29.8%)
Slight	388 (28.5%)
Moderate	306 (22.5%)
Extreme	263 (19.3%)
Internalized stigma***	
No	544 (39.9%)
Slight	282 (20.7%)
Moderate	313 (23.0%)
Extreme	224 (16.4%)

*2, 79, 5, 5, 2, and 1 Individuals have missing information on ART experience, CD4 count, viral load, injection drug use, homelessness, and violence experience, respectively;
HIV or sex work related stigma, ever; details on stigma measures in **Appendix A1; ***sex work related; details on stigma measures in **Appendix A1**;
Abbreviations: ART, antiretroviral treatment.



Figure 1. Health-related quality of life profile of female sex workers living with HIV in Durban, South Africa, 2018-2020. (A) Proportion of women reporting problems on each EQ-5D-3L domain. (B) Most frequent EQ-5D-3L health states. For example, health state 11123 refers to no problems in mobility, self-care and usual activity, moderate problems in pain/discomfort, and extreme problems in anxiety/depression. (C) Distribution of EQ-5D-3L preference-weighted summary index (HRQoL score, representing health utility), in which 1 denotes no problems in any of the five domains and 0 denotes a health state equivalent to death. (D) Distribution of EQ-5D visual analogue scale, in which participants are asked to rate their quality of life on a “thermometer” from 0 (equivalent to death) to 100 (perfect health). Abbreviations: EQ-5D-3L, EuroQoL five dimensions, three levels; HRQoL, health-related quality of life.

Table 2. EQ-5D health-related quality of life (HRQoL) score* and visual analogue scale (EQ-VAS) among female sex workers living with HIV in Durban, South Africa, 2018-2020.

	EQ-5D HRQoL score			EQ-VAS		
Characteristics	Mean (SD)	Median (IQR)	P-value**	Mean (SD)	Median (IQR)	P-value**
Total	0.857 (0.187)	1.00 [0.787, 1.00]		57.7 (21.9)	52.0 [50.0, 70.0]	
Age in years			**0.004**			0.18
18-24	0.891 (0.157)	1.00 [0.787, 1.00]		57.5 (21.1)	53.0 [50.0, 70.0]	
25-34	0.859 (0.189)	1.00 [0.787, 1.00]		57.2 (22.2)	52.0 [50.0, 70.0]	
35-44	0.846 (0.191)	0.854 [0.787, 1.00]		57.5 (21.5)	52.0 [50.0, 70.0]	
45-65	0.811 (0.210)	0.854 [0.727, 1.00]		62.1 (21.8)	58.0 [50.0, 80.0]	
Self-identified as black race			**0.008**			0.97
Yes	0.859 (0.186)	1.00 [0.787, 1.00]		57.8 (21.7)	52.0 [50.0, 70.0]	
No	0.776 (0.207)	0.854 [0.660, 1.00]		56.3 (25.8)	55.5 [47.5, 74.3]	
Completed secondary school or higher			0.31			0.42
Yes	0.866 (0.184)	1.00 [0.787, 1.00]		58.8 (24.7)	54.0 [47.0, 75.5]	
No	0.855 (0.188)	1.00 [0.787, 1.00]		57.5 (21.1)	52.0 [50.0, 70.0]	
ART experience			**0.004**			**<0.001**
ART naive	0.842 (0.195)	0.854 [0.787, 1.00]		54.2 (20.5)	51.0 [45.0, 62.0]	
Currently off ART	0.827 (0.206)	0.854 [0.727, 1.00]		49.1 (21.7)	50.0 [40.0, 60.0]	
Currently on ART	0.870 (0.177)	1.00 [0.787, 1.00]		61.4 (21.2)	56.0 [50.0, 75.0]	
CD4, cells/mm^3			0.76			**<0.001**
≥500	0.855 (0.183)	1.00 [0.787, 1.00]		59.4 (22.8)	54.0 [50.0, 75.0]	
350-499	0.860 (0.196)	1.00 [0.787, 1.00]		57.6 (21.0)	52.0 [50.0, 70.0]	
200-349	0.865 (0.175)	1.00 [0.787, 1.00]		53.6 (20.0)	50.0 [45.0, 62.0]	
<200	0.846 (0.204)	1.00 [0.787, 1.00]		55.7 (20.6)	52.0 [47.8, 70.0]	
Viral load, copies/ml			0.62			**<0.001**
<50	0.860 (0.180)	1.00 [0.787, 1.00]		61.6 (21.7)	56.0 [50.0, 75.8]	
50-1000	0.847 (0.192)	1.00 [0.744, 1.00]		57.4 (21.8)	51.0 [50.0, 70.0]	
>1000	0.859 (0.191)	1.00 [0.787, 1.00]		54.8 (21.6)	51.0 [45.0, 67.0]	
Drug use, past 30 days			**<0.001**			**<0.001**
Yes	0.844 (0.191)	0.854 [0.787, 1.00]		55.8 (21.7)	51.0 [47.0, 70.0]	
No	0.879 (0.178)	1.00 [0.787, 1.00]		61.0 (21.8)	56.0 [50.0, 75.0]	
Injection drug use, ever			0.95			0.082
Yes	0.861 (0.177)	1.00 [0.787, 1.00]		54.1 (17.6)	50.0 [45.0, 63.5]	
No	0.857 (0.187)	1.00 [0.787, 1.00]		57.8 (22.0)	52.0 [50.0, 70.0]	
Homelessness, past 6 months			**0.014**			**<0.001**
Yes	0.840 (0.194)	0.854 [0.777, 1.00]		54.5 (21.4)	51.0 [45.0, 65.0]	
No	0.864 (0.184)	1.00 [0.787, 1.00]		59.1 (21.9)	54.0 [50.0, 72.0]	
Experience of physical or sexual violence, ever			**<0.001**			**<0.001**
Yes	0.837 (0.197)	0.854 [0.777, 1.00]		55.0 (21.4)	51.0 [47.0, 67.0]	
No	0.888 (0.165)	1.00 [0.787, 1.00]		62.0 (21.9)	56.0 [50.0, 80.0]	
Experience with stigma ***			0.33			**<0.001**
No	0.858 (0.188)	1.00 [0.787, 1.00]		62.0 (22.5)	57.5 [50.0, 80.0]	
Slight	0.861 (0.189)	1.00 [0.787, 1.00]		60.0 (19.7)	53.5 [50.0, 71.0]	
Moderate	0.863 (0.184)	1.00 [0.787, 1.00]		54.5 (21.3)	51.0 [46.3, 69.0]	
Extreme	0.844 (0.186)	0.854 [0.787, 1.00]		51.4 (22.5)	50.0 [40.5, 61.5]	
Internalized stigma****			0.07			**<0.001**
No	0.868 (0.178)	1.00 [0.787, 1.00]		60.0 (21.2)	54.0 [50.0, 71.0]	
Slight	0.858 (0.186)	1.00 [0.787, 1.00]		60.2 (21.2)	55.0 [50.0, 73.8]	
Moderate	0.830 (0.204)	0.854 [0.787, 1.00]		56.9 (22.2)	52.0 [43.0, 70.0]	
Extreme	0.867 (0.182)	1.00 [0.787, 1.00]		50.3 (22.2)	50.0 [41.0, 60.0]	

*HRQoL score was calculated using the Zimbabwe general population value set; **Wilcoxon rank sum tests, and Kruskal-Wallis tests were used to compare median values in the HRQoL score and EQ-VAS by binary variables and by other categorical variables, respectively; ***HIV or sex work related stigma, ever; details on stigma measures in **Appendix A1**; ****sex work related; details on stigma measures in **Appendix A1**;

Abbreviations: EQ-5D, EuroQoL five dimension; SD, standard deviation; IQR, inter quartile range; ART, antiretroviral treatment.

Table 3. Multivariable analyses of factors associated with the EQ-5D health-related quality of life (HRQoL) score and the visual analogue scale (EQ-VAS) of female sex workers living with HIV in Durban, South Africa, 2018-2020.

	Average marginal change in EQ-5D HRQoL score*				Average marginal chang in EQ-VAS**		
Characteristics	Point	Lower	Upper	P-value	Point	Lower	Upper
Age in years (per ten-year increase)	**-0.018**	**-0.027**	**-0.008**	**<0.001**	0.005	-0.020	0.011
Completed secondary school or higher (yes vs no)	0.006	-0.011	0.022	0.49	0.014	-0.015	0.043
Current on ART (yes vs no)	**0.015**	**-0.001**	**0.031**	**0.062**	**0.080**	**0.054**	**0.106**
CD4<200, cells/mm^3 (yes vs no)	-0.002	-0.023	0.019	0.85	-0.011	-0.046	0.024
Viral suppression (<50 copies/ml) (yes vs no)	-0.008	-0.024	0.008	0.32	0.021	-0.005	0.048
Drug use, past 30 days (yes vs no)	**-0.022**	**-0.036**	**-0.007**	**0.003**	-0.018	-0.043	0.007
Homelessness, past 6 months (yes vs no)	-0.008	-0.024	0.007	0.29	**-0.027**	**-0.053**	**-0.001**
Experience of physical or sexual violence, ever (yes vs no)	**-0.024**	**-0.038**	**-0.010**	**<0.001**	**-0.036**	**-0.060**	**-0.012**
Experience with stigma (slight vs no)***	0.005	-0.013	0.022	0.61	-0.012	-0.042	0.018
Experience with stigma (moderate vs no)***	0.011	-0.008	0.029	0.25	**-0.059**	**-0.092**	**-0.027**
Experience with stigma (extreme vs no)***	-0.002	-0.023	0.019	0.86	**-0.078**	**-0.112**	**-0.043**
Internalized stigma (slight vs no)****	-0.008	-0.026	0.010	0.37	0.000	-0.031	0.031
Internalized stigma (moderate vs no) ****	**-0.023**	**-0.041**	**-0.004**	**0.016**	**-0.042**	**-0.072**	**-0.012**
Internalized stigma (extreme vs no) ****	0.000	-0.018	0.019	0.98	**-0.085**	**-0.119**	**-0.052**

*Estimated using beta regression with complementary loglog link; the HRQoL score was calculated using the Zimbabwe general population value set; **Estimated using linear regression; EQ-VAS scaled to 0-1 from 0-100; ***HIV or sex work related stigma, ever; details on stigma measures in **Appendix A1**; ****sex work related; details on stigma measures in **Appendix A1**; Abbreviations: EQ-5D, EuroQoL five dimension; ART, antiretroviral treatment.



Figure 2. Estimated mean and 95% confidence intervals of health-related quality of life (HRQoL) score (representing health utility) for subgroups of female sex workers (FSW) living with HIV in Durban, South Africa by current antiretroviral treatment (ART) use. Values estimated using the fitted multivariable beta regression model, setting the rest of covariates (age, education, CD4 count, viral suppression, homelessness, experience with stigma and internalized stigma) at the sample average values.